Agilent updates Visiopharm image analysis software

By staff writers

October 8, 2020 -- Agilent Technologies has released an updated version of its Visiopharm image analysis software. The software now incorporates HercepTest monoclonal antibody (mAb) pharmDx for Dako Omnis.

The upgrade will allow pathologists to use Visiopharm HER2 App for breast cancer treatment decision support as they assess HercepTest mAb pharmDx slides.

HercepTest mAb pharmDx is used for breast cancer patients who are under consideration for Herceptin treatment; if HER2 is overexpressed, the patient may be a candidate, Agilent said.

FDA approves Agilent assay for lung cancer
The U.S. Food and Drug Administration (FDA) has cleared Agilent Technologies' companion diagnostic assay for use in guiding immunotherapy treatment in...
Agilent launches liquid chromatography-mass spectrometry system in U.S.
Agilent Technologies has announced the U.S. launch of a new liquid chromatography-mass spectrometry system designed to improve diagnostic workflow in...
Agilent's PD-L1 test gets OK for head, neck cancer in Europe
Agilent Technologies' programmed cell death ligand 1 (PD-L1) immunohistochemistry (IHC) 22C3 pharmDx assay has been labeled for use in patients with head...
Agilent gets green light in China for PD-L1 companion test
Agilent Technologies has received approval in China for its programmed cell death ligand 1 (PD-L1) immunohistochemistry (IHC) 22C3 pharmDx assay in lung...
Agilent christens new R&D center in Singapore
The National University of Singapore, the National University Hospital, and Agilent Technologies officially launched a 38 million Singapore dollar...

Copyright © 2020

Last Updated bc 10/9/2020 1:42:45 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.